New Exosome-Based COVID booster enters human testing
NCT ID NCT07095231
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new COVID-19 booster vaccine, STX-S, in 60 healthy adults who had already received a primary vaccine series and at least one booster. The vaccine uses tiny particles called exosomes to deliver spike proteins. The main goal was to check safety and side effects at three different doses, while also measuring immune responses in the blood and nose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STX-S (an experimental vaccine using exosomes to deliver spike proteins)
What this could lead to
If successful, this could lead to a new type of COVID-19 booster that may offer better or longer-lasting protection.
What could go wrong
This is a very early Phase 1 trial with only 60 people, so safety and immune response are still unknown. It may not work as hoped or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaiser Permanente Washington Health Research Institute
Seattle, Washington, 98101-1466, United States
-
The University of Washington - Virology Research Clinic
Seattle, Washington, 98104, United States
-
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York, 14642-0001, United States